期刊文献+

重组人5型腺病毒对B16黑色素瘤生长的抑制作用 被引量:2

Anti-Tumor Effect of a Replication-Selective Oncolytic Adenovirus(H101) on Mice Bearing B16 Melanoma
下载PDF
导出
摘要 目的研究瘤内直接注射重组人5型腺病毒H101对B16黑色素瘤生长以及对手术后再次接种B16黑色素瘤细胞后肿瘤生长的影响。方法建立小鼠B16黑色素瘤动物模型。瘤内直接注射H101腺病毒,测量肿瘤体积,切除肿瘤,再次接种B16黑色素瘤细胞,观察肿瘤生长情况。结果细胞接种8 d后,全部小鼠均长出肿瘤。H101注射组肿瘤的体积在给药后3,6,9 d,都显著小于对照组。再次接种B16黑色素瘤细胞后,H101注射组肿瘤的生长速度也显著小于对照组。结论瘤内直接注射H101对B16黑色素瘤生长具有抑制作用,对手术后再次接种的肿瘤生长也具有抑制作用。 OBJECTIVE To study the inhibition effects of direct intratumor injection of H101 on B16 melanoma in C57/BL6 mice and syngenetic mice rechallenged with parental cells. METHODS C57/BL6 mice bearing B16 melanoma were established by subcutaneous seeding B16 cell suspension at a dose of 2 × 10^6 cells per mouse. H101 was injected directly into the tumor in three continuous days at a dose of 5 × 10^6 pfu · mm-3 · d^-1. The tumors were surgically excised 7 days after the injection of H101. At 14 days after surgery, all animals were rechallenged on the opposite flank with parental B16 cell at a dose of 2 × 10^5 cells. The tumor size was calculated every day to observe the antitumor effect. RESULTS The average tumor volume in the H101 injection group was signifi- cantly smaller than that in control group, not only at D3, D6 and D9, but also at every day for the surgery mice rechallenged with parental cells. CONCLUSION The direct injection of H101 showed potent antitumor effect on B16 melanoma.
出处 《中国药学杂志》 CAS CSCD 北大核心 2007年第21期1633-1635,共3页 Chinese Pharmaceutical Journal
基金 国家自然科学基金资助项目(30371614) 国家科技部创新药物和中药现代化863重大专项课题资助项目(2002AA2Z3304)
关键词 黑色素瘤 重组人5型腺病毒H101 基因治疗 melanoma A gene engineered adenovirus ( H101 ) gene therapy
  • 相关文献

参考文献10

  • 1钱其军,吴孟超,王晋,刘新垣,车小燕,岑信棠.恶性肿瘤治疗的新策略——基因-病毒治疗[J].肿瘤学杂志,2001,7(4):193-195. 被引量:2
  • 2WANG Y, HU F. Clinical trials with oncolytic adenovirus in China [ J ]. Current Drug Targets, 2007,7 ( 2 ) :659-670. 被引量:1
  • 3叶玲,钱关祥,葛盛芳.E1B缺失腺病毒H101的研究进展[J].肿瘤研究与临床,2007,19(6):429-432. 被引量:1
  • 4VORBURGER S A, HUNT K K. Adenoviral gene therapy[J]. The Oncologist , 2002, 7:46-59. 被引量:1
  • 5张波,邹卫国,吴国豪,靳大勇,许德华,郑仲承,吴肇汉,刘新垣.人内皮抑素转基因治疗B16黑色素瘤的实验研究[J].中华肿瘤杂志,2002,24(5):451-454. 被引量:8
  • 6BISCHOFF J R, KIRN D H, WILLIAMS A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells[J]. Sci, 1996, 274 (5286):373-376. 被引量:1
  • 7BIEDERER C, RIES S, BRANDTS C H, et al. Replication-selective viruses for cancer therapy [ J ]. J Mol Med, 2002, 80 (3) : 163-175. 被引量:1
  • 8MELCHER A, MURPHY S, VILE R. Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors[J]. Hum Gene Ther, 1999, 10 (9) :1431-1442. 被引量:1
  • 9MELCHER A, TODRYK S, HARDWICK N, et al. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression[ J]. Nat Med, 1998, 4 (5) :581-587. 被引量:1
  • 10VILE R G, HART I R. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA[J]. Cancer Res, 1993, 53 (17) :3860-3864. 被引量:1

二级参考文献31

共引文献8

同被引文献51

  • 1解春文,解春艳.重组人-p53腺病毒注射液[J].中外医疗,2008,27(17):21-22. 被引量:9
  • 2丁娅,张晓实,彭瑞清,张蓉,张念华,李志铭,刘继彦,马锦,程霞,苏义顺,曾益新.重组人p53腺病毒注射液治疗晚期实体肿瘤的安全性和近期疗效评价[J].中国临床药理学与治疗学,2005,10(9):1025-1029. 被引量:10
  • 3戚晓东,杨之斌,韩德民,倪鑫,牛旗,李志新,姜乃佳.“今又生”治疗晚期恶性肿瘤的疗效观察(附23例)[J].现代肿瘤医学,2006,14(10):1295-1297. 被引量:19
  • 4中国化学制药工业协会.2013全球十大畅销药物排行榜的前世今生[EB/OL].(2014-10-19).http://www.cpia.org.on/contents/4/181897.html. 被引量:1
  • 5TANGO Y, TAKI M, SHIRAKIYA Y. et al. Late resistance to adenoviral p53-mediated apoptosis caused by decreased expres- sion of Coxsackie-adenovirus receptor in human lung cancers [ J ]. Cancer Sci, 2004,95 (5) :459 - 463. 被引量:1
  • 6彭朝晖,张晓志.病毒载体与人肿瘤抑制基因的重组体及其应用:中国,02115228.4[P].2003-03-12. 被引量:1
  • 7GARBER K. China approves world's first oneolytic virus therapy for cancer treatment [ J ]. J Natl Cancer lnst, 2006,98 ( 5 ) : 298 - 300. 被引量:1
  • 8KAUFMAN HL, BINES SD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM CSF for unresectable stage III or IV melanoma[J]. Future Oncol, 2010,6(6) ,941 -949. 被引量:1
  • 9ANDTBACKA RHI, COLLICHIO FA, AMATRUDA T, et al. OPTiM : A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous ( SC ) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma [ J]. J Clin Ortcal, 2013, 31(18) :LBA9008. 被引量:1
  • 10张晖.基因工程腺病毒及其用途:中国,98103219.2[P].2000-01-19. 被引量:1

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部